|Articles|February 9, 2022

Retrofit Pharmaceutical Equipment for High Containment and Reduced Risk of Cross Contamination

Author(s)ILC Dover

With the growth of highly potent active pharmaceutical ingredients (HPAPIs) and multiple-use facilities that must protect against product cross contamination, the need for engineering controls to achieve high containment has become more critical.


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.